Psyence Biomedical Limited - PBM Net earnings per share growth forecast for next year

The stable operation of processing facilities and mining equipment at Psyence Biomedical Ltd. (PBM) creates a foundation for growth, as evidenced by the consensus EPS n+1 forecast chart, where the figure remains at 0.00. Optimism is further bolstered by the diversification of exploration in safe-haven regions; however, asset valuation remains dependent on gold and copper price volatility during market cycle shifts.

Psyence Biomedical Limited (PBM): Net earnings per share change forecast for next year from 02/21/2024 to 11/15/2026

Metric breakdowns and analytics for Psyence Biomedical (PBM)

- share price and consensus valuation forecast:

Stock Price Psyence Biomedical Ltd.|PBM - Fair Value Consensus

- issuer market value details:

Market Value Psyence Biomedical|PBM - Total Enterprise Value

- company book value details:

Net Assets per Single Share Psyence Biomedical|PBM - Net Asset Value|Market Value to Book Value Ratio pacificbayminerals.com|PBM - Company Total Asset Base

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

PBM - Company Net Income|Future Profit Psyence Biomedical Ltd.|PBM - Company Value to Net Income|Forward P/E Multiple Psyence Biomedical|PBM - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Psyence Bio|PBM - Operating income before deduction of amortization|Earnings per share for the last twelve months Psyence Biomedical|PBM - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months pacificbayminerals.com|PBM - Net earnings per share growth this year|Earnings growth forecast for next year Psyence Biomedical Ltd.

- sales revenue and business income indicators:

PBM - Company Total Revenue|Projected Sales Volume Psyence Biomedical|PBM - Market Cap to Revenue Ratio|Forward P/S Multiple Psyence Bio

Fundamental company analysis:PBM, Psyence Biomedical

For Psyence Biomedical Ltd. (PBM), which is currently in the R&D stage of psilocybin therapy, the market consensus reflects a balance between high development risks and the potential of the palliative market. By analyzing the target net earnings per share growth rate, investors can observe the trend of institutional revisions to future revenues, allowing for an objective assessment of the business's fundamental value amid macroeconomic volatility.

Competing companies